Insights from Frost & Sullivan: Why China's CDMO Development Matters
Frost & Sullivan has released the 2025 China Pharmaceutical CDMO Industry Insight Blue Book, offering an authoritative perspective on the rapid evolution of China’s CDMO sector. We are honored that ChemExpress is recognized in this report as a representative enterprise, which reflects our contributions to the industry’s advancement.
The report emphasizes that partnerships with CDMOs have become indispensable in innovative drug development. As drug molecules become more complex and commercialization accelerates, CDMOs are shifting from traditional outsourcing roles to strategic partners. By working with experienced CDMOs, global pharmaceutical and biotech companies can:
Therefore, CDMOs are becoming an essential enabler of innovative drug development.
The Blue Book shows that China’s CDMO market is demonstrating continued growth momentum, driven by several factors:
Among the various molecule types, ADCs have shown particularly strong momentum, with high technical barriers and rising global demand, making them an important focus for next-generation oncology therapies. This momentum closely aligns with ChemExpress’s business scope. Recognized in the report as a representative enterprise, ChemExpress offers integrated CDMO solutions across ADCs, small molecules, and biologics.
ChemExpress provides comprehensive end-to-end CDMO solutions across small molecules, ADCs, and biologics. In ADC development, ChemExpress has established strong expertise—supported by extensive payload and linker libraries, GMP-compliant facilities, and a robust global project track record. Through these capabilities, ChemExpress helps partners streamline complex projects under a unified quality system, reduce risks, and accelerate the development of next-generation therapeutics.
We are pleased that the growth of China’s CDMO industry is being recognized globally. At ChemExpress, we will continue to work alongside innovators worldwide—delivering efficient, high-quality, and trusted solutions that empower the future of drug development.
